Biogen | BIIB - Ebit


Biogen reported $419.5M in EBIT for its fiscal quarter ending in September of 2026.





Ebit Change Date
AbbVie USD 6.72B 1.99B Jun/2026
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
ALKERMES USD -65.93M 17.65M Jun/2026
Amgen USD 4.61B 777M Jun/2026
Bayer EUR 755M 2.77B Jun/2026
Biogen USD 419.5M 663.3M Sep/2026
BioMarin Pharmaceutical USD 105.6M 24.04M Jun/2026
Bristol-Myers Squibb USD 299M 3.26B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Incyte USD 700.4M 356.23M Jun/2026
Merck USD 840M 2.72B Jun/2026
Moderna USD -815M 573M Jun/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Novartis USD 4.73B 549M Jun/2026
Pfizer USD -180M 5.16B Jun/2026
PTC Therapeutics USD 146.03M 100.14M Jun/2026
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Sanofi EUR 1.12B 811M Jun/2026
Sanofi EUR 2.18B 1.56B Mar/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
Teva Pharmaceutical Industries USD 235M 523M Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
United Therapeutics USD 375.6M 49.8M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026